Clinical Trial Detail

NCT ID NCT04434040
Title Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab + Ipatasertib

Age Groups: adult senior

No variant requirements are available.